Use Salix Pharmaceuticals Ltd. story together with your assets to enhance returns of your portfolios as well as to check it against diversification policy that fits your risk preferences.
This story from stocks.us.reuters.com contributed to next trading day price increase. The story delta to the next closing price was 2.71% . The story delta to the current price is 65.64% .
IT Business Net - May 10, 2012
By GrabNetworks Salix Pharmaceuticals (SLXP) today had its estimates increased by Jefferies (JEF) after the company beat earnings estimates.
Junction Report - May 9, 2012
Salix Pharmaceuticals (NASDAQ: SLXP)'s stock had its ?neutral? rating restated by Zacks in a report issued on Wednesday. They currently have a $55.00 target price on the stock.
Auriga Reiterates Hold on Salix Pharmaceuticals (SLXP) - Movie News Guide (blog)
StreetInsider.com (subscription) - May 8, 2012
Jefferies analysts raised their price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $54.00 to $63.00 while maintaining a BUY rating on the company.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of business and is important item when evaluating financial statements of a company. Revenues from a firm's main business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which given company operates.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
